Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — FY2019 Earnings Presentation
27 slides from Orion Oyj Class A's earnings presentation, Feb 5, 2020
Slide 1: Orion Result presentation 1−12/2019
Orion Result presentation 1−12/2019
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Highlights in January-December 2019
Highlights in January-December 2019
Slide 4: Darolutamide dominated news flow in 2019
Darolutamide dominated news flow in 2019 1 Darolutamide received MA in the USA and Brazil. In Japan, MA in Jan/2020. CHMP recommendation for 3 All business units reported growth in net sales. darolutamide in EU. Darolutamide showed statistically significant REFALS patient recruitment improvement in
Slide 5: Key figures 1−12/2019
Key figures 1−12/2019 Net sales Operating profit Operating profit Cash flow per share margin before financial items* 1,051 253 24% 1.68 MEUR (977) MEUR (253) (26%) EUR (2.32) +8% -27% *) Comparison period cash flow per share before financial items includes both continuing and discontinued operations
Slide 6: Development of net sales and operating profit
Development of net sales and operating profit Net sales Operating profit 10 5 1,051 40 -3 -29 13 8 19 -18 14 -12 45 253 3 253 977 -13 -8 * Product sales without sales margin and product mix change and exchange rate effect *** Exchange rate effect on gross margin ** Product sales margin and product m
Slide 7: Geographical breakdown and development of net sales
Geographical breakdown and development of net sales 1-12/2019 MEUR 1-12/2019 1-12/2018 12% 400 +10% 29% 350 -1% 10% 300 250 +14% -13% 200 +76% 150 32% 17% 100 50 Finland Scandinavia 0 Other Europe North America ROW Result presentation 2019 © Orion Corporation 5 February 2020
Slide 8: All business units showed growth
All business units showed growth 1−12/2019 1−12/2018 1-12/2019 MEUR +3% 600 +14% 5% 2% 486 473 8% 500 406 400 357 39% 300 +7% 200 +8% 46% +11% 86 80 100 55 51 18 16 Proprietary Products 0 Specialty Products Specialty Proprietary Animal Fermion CM* & Animal Health Products Products Health other Fermi
Slide 9: Best-selling pharmaceuticals 1−12/2019
Best-selling pharmaceuticals 1−12/2019 Net sales Change vs. . Indication EUR million 1−12/2018 1. Asthma, COPD 104 +16% 2. Parkinson’s disease 98 -3% 3. Acute heart failure 68 +14% 4. Intensive care sedative 57 -10% Rheumatoid arthritis, inflammatory 5. Biosimilars bowel diseases, lymphoma 38 +52% 6
Slide 10: Proprietary Products
Proprietary Products
Slide 11: Easyhaler® product family and Simdax® growing
Easyhaler® product family and Simdax® growing Proprietary Products +16% -3% sales split 1-12/2019 MEUR 120 104 100 98 19% 100 90 -10% +14% 24% 80 68 63 59 57 60 40 17% 20 26% 0 14% Easyhaler® Parkinson Dexdor® Simdax® Parkinson Easyhaler® franchise Dexdor® Simdax® 1−12/2019 1−12/2018 Muut Result pre
Slide 12: Easyhaler® sales exceeded EUR 100 million
Easyhaler® sales exceeded EUR 100 million Sales, EUR million 35 ● Budesonide-formoterol Easyhaler® +21% 30 continued strong growth. 25 20 ● Product family total sales : +16% 15 10 ● Salmeterol-fluticasone sales developed slower than anticipated. 5 0 ● Development of Easyhaler® tiotropium continues.
Slide 13: Share of Orion's own sales in Parkinson increased
Share of Orion’s own sales in Parkinson increased Sales, MEUR million 50 45 40 35 30 25 20 15 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2014 2015 2016 2017 2018 2019 Orion's own sales Parkinson (Stalevo®, Comtan®) deliveries to partners Result presentation 2019 ©
Slide 14: Sales of Dexdor® declining due to generic competition
Sales of Dexdor® declining due to generic competition Total value of European sedatives market: EUR 595 million (+4%) Sales, EUR million 12% 20 18 16 12% 14 66% 12 10 8 10% 6 4 2 Propofol 393 Meur (+7%) 0 Midazolam 61 Meur (-2%) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Dexmedetomi
Slide 15: Specialty Products
Specialty Products
Slide 16: Specialty Products: tight price competition continued
Specialty Products: tight price competition continued Development of net sales Net sales by region Net sales by products 1−12/2019 1−12/2019 MEUR -0% 8% 300 272 273 12% 250 14% 24% 200 +28% +2% 150 56% 89 100 69 68 18% 66 68% 50 0 Finland Generic drugs Finland Scandinavia Eastern Scandinavia Europe
Slide 17: Price competition and market decline of reference priced prescription drugs in Finland
In Finland, price competition and product deficiencies behind the market decline of reference priced prescription drugs The market of reference priced The sales of Orion's reference prescription drugs in Finland priced prescription drugs (1−12/2019) in Finland MEUR 436 (455) MEUR 116 (123) Market de
Slide 18: Orion is strong in home market Finland
Orion is strong in home market Finland Human pharma market in Finland 1−12/2019 Reference Self-care Medicinal and non-medicinal products priced products in hospital and pharmacy channels: EUR 2,859 million prescription Orion market share in MEUR drugs pharmacy 350 314 Orion market share in 300 pharm
Slide 19: Research and development
Research and development
Slide 20: Orion's key clinical drug development projects
Orion's key clinical drug development projects Project Indication Phase Registration Easyhaler® tiotropium COPD Bioequivalence study Darolutamide 1) Prostate cancer (nmCRPC) I II III Registration Darolutamide 1) Prostate cancer (mHSPC) I II III ODM-109 (oral levosimendan) ALS I II III ODM-203 (targe
Slide 21: Orion's key business targets in 2019-2020
Orion's key business targets in 2019-2020 Commercialisation of darolutamide in • MA received in USA, Japan and Brazil. Positive CHMP Europe. ARASENS trial (metastatic 1. prostate cancer) continues in order to recommendation in EU. expand the indication for the molecule. • Fully recruited ARASENS tri
Slide 22: Orion's key business targets in 2019-2020
Orion's key business targets in 2019-2020 Strengthening Orion’s position as the most • Orion clear market leader in significant provider of generic drugs in reference priced prescription 3. Finland. Competitive product portfolio in drugs in Finland. Specialty Products and strengthening of • In self-
Slide 23: Material themes of Orion's sustainability
Material themes of Orion’s sustainability Ensuring patient safety and reliable supply of medications. Responsibility for the environment, employees and the ethics and transparency of operations. Customer Audits undertaken Greenhouse gas Energy savings Injury rate complaints by Orion emissions (scope
Slide 24: Outlook
Outlook
Slide 25: Outlook for 2020
Outlook for 2020 Net sales Orion estimates that in 2020 the net sales will be at a similar level as in 2019 (the net sales in 2019 were EUR 1,051 million). Operating profit The operating profit is estimated to be lower than in 2019 (the operating profit in 2019 was EUR 253 million). Result presentat
Slide 26: Orion calendar
Orion calendar Annual General Meeting 25/3/2020 Interim Report 1-3/2020 28/4/2020 Half-Year Report 1-6/2020 17/7/2020 Interim Report 1-9/2020 21/10/2020
Slide 27: Building well-being
Building well-being